Public Release: 

Advances in deep learning for biomarker development to be presented at the PMWC in Silicon Valley

InSilico Medicine, Inc.

Thursday, Jan. 18th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, is pleased to announce the lecture of its founder and CEO, Dr. Alex Zhavoronkov, at the Precision Medicine World Conference (PMWC) 2018, January 23, 2018, Silicon Valley.

The AI panel will focus on the latest advances in artificial intelligence for biomarker development and drug discovery. The session will cover different approaches and AI platforms, and how they impact the pharmaceutical industry and specifically, the drug discovery and development processes.

"PMWC Silicon Valley is one of the top conferences in biomedicine and we are very happy to be back this year after receiving the Most Promising Company award at the conference in 2015, when deep learning was still an exotic term. This year's conference is heavily focused on AI and the organizers managed to gather pretty much everyone in the field in the Computer History Museum", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

The Precision Medicine World Conference is an independent and established conference series known as prominent medicine conference gathering recognized leaders, top global researchers, medical professionals and innovators across healthcare and biotechnology to close the gap between different sectors and to catalyze the cross-functional collaborations. The program of PMWC Silicon Valley embaraces innovative technologies, growing initiatives, and clinical case studies converting the advances of precision medicine into direct improvements in health care. The conference agenda highlights more than 70 sessions with 350+ talks covering all facets of precision medicine. The event will transpire January 22-24, 2018.

Insilico Medicine is regularly publishing research papers in peer reviewed journals. It was the first company applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. The latest paper published in the Journals of Gerontology exhibited the new artificial intelligence algorithm determining the biological age with high precision and having a potential to reveal whether lifestyle changes and medicinal products can increase people's chances of living a long and healthy life.


For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
a href="">


Official Conference Website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.